CMS is approving this time-limited state plan amendment to respond to the COVID-19 national emergency. The purpose of this amendment is to 1) waive signature requirements for the dispensing of drugs during the COVID-19 public health emergency; and 2) authorize reimbursement rates for COVID-19 monoclonal antibody treatment and administration that are set equal to 100% of the Medicare national payment allowance reimbursement rate or comparable code.
State
Approval Date
Effective Date
File 1 - Approval Document Media